Pharma Co. Must Face Investor Suit Over Cancer Drug Study

By Sydney Price · January 23, 2024, 9:38 PM EST

Spectrum Pharmaceuticals must face a consolidated proposed securities class action alleging it misled investors about a lung cancer treatment drug study after a New York federal judge decided Tuesday that the...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Ayoub, et al v. Spectrum Pharmaceuticals, Inc. et al

Case Number

1:22-cv-10292

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

December 05, 2022